1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D’ Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD, EuroSIDA study group: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003, 362 (9377): 22-29. 10.1016/S0140-6736(03)13802-0.
2. Delaugerre C, Ghosn J, Lacombe J-M, Pialoux G, Cuzin L, Launay O, Menard A, de Truchis P, Costagliola D: FHDH ANRS CO04. Trend over calendar time in virological failure in HIV-infected patients treated for at least six months with combined antiretroviral therapy in France (FHDH ANRS CO04). Paper presented at: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011, Rome, Italy: Abstract TUPDB0104
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.
http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
,
4. Morlat P: Recommandations du groupe d’experts 2013. Prise en charge médicale des personnes vivant avec le VIH.
http://www.sante.gouv.fr/rapport-2013-sur-la-prise-en-charge-medicale-des-personnes-vivant-avec-le-vih.html
,
5. French MA, King MS, Tschampa JM, da Silva BA, Landay AL: Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009, 200 (8): 1212-1215. 10.1086/605890.